Inspire Medical Systems (INSP)
Market Price (2/3/2026): $74.66 | Market Cap: $2.2 BilSector: Health Care | Industry: Health Care Equipment
Inspire Medical Systems (INSP)
Market Price (2/3/2026): $74.66Market Cap: $2.2 BilSector: Health CareIndustry: Health Care Equipment
Investment Highlights Why It Matters Detailed financial logic regarding cash flow yields vs trend-riding momentum.
| Cash is significant % of market capNet D/ENet Debt/Equity. Debt net of cash. Negative indicates net cash. Equity is taken as the Market Capitalization is -13% | Weak multi-year price returns2Y Excs Rtn is -108%, 3Y Excs Rtn is -143% | Expensive valuation multiplesP/EBITPrice/EBIT or Price/(Operating Income) ratio is 46x, P/EPrice/Earnings or Price/(Net Income) is 48x |
| Attractive cash flow generationCFO/Rev LTMCash Flow from Operations / Revenue (Sales), Last Twelve Months (LTM) is 15%, FCF/Rev LTMFree Cash Flow / Revenue (Sales), Last Twelve Months (LTM) is 11% | Meaningful short interestShort Interest % of Basic SharesShort Interest % of Basic Shares = (Short Interest Quantity) / (Basic Shares Outstanding). A high fraction of short interest can indicate potential risk of a short squeeze. is 10% | Significant share based compensationSBC/Rev LTMShare Based Compensation / Revenue (Sales), Last Twelve Months (LTM) is 15% |
| Megatrend and thematic driversMegatrends include Precision Medicine, Digital Health & Telemedicine, and Aging Population & Chronic Disease. Themes include Targeted Therapies, Show more. | Yield minus risk free rate is negativeERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -2.1% | |
| Key risksINSP key risks include [1] execution failures and legal challenges from its Inspire V product launch, Show more. |
| Cash is significant % of market capNet D/ENet Debt/Equity. Debt net of cash. Negative indicates net cash. Equity is taken as the Market Capitalization is -13% |
| Attractive cash flow generationCFO/Rev LTMCash Flow from Operations / Revenue (Sales), Last Twelve Months (LTM) is 15%, FCF/Rev LTMFree Cash Flow / Revenue (Sales), Last Twelve Months (LTM) is 11% |
| Megatrend and thematic driversMegatrends include Precision Medicine, Digital Health & Telemedicine, and Aging Population & Chronic Disease. Themes include Targeted Therapies, Show more. |
| Weak multi-year price returns2Y Excs Rtn is -108%, 3Y Excs Rtn is -143% |
| Meaningful short interestShort Interest % of Basic SharesShort Interest % of Basic Shares = (Short Interest Quantity) / (Basic Shares Outstanding). A high fraction of short interest can indicate potential risk of a short squeeze. is 10% |
| Expensive valuation multiplesP/EBITPrice/EBIT or Price/(Operating Income) ratio is 46x, P/EPrice/Earnings or Price/(Net Income) is 48x |
| Significant share based compensationSBC/Rev LTMShare Based Compensation / Revenue (Sales), Last Twelve Months (LTM) is 15% |
| Yield minus risk free rate is negativeERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -2.1% |
| Key risksINSP key risks include [1] execution failures and legal challenges from its Inspire V product launch, Show more. |
Qualitative Assessment
AI Analysis | Feedback
1. Mixed Reactions to Financial Updates. Inspire Medical Systems experienced a positive stock movement in early November 2025 following its stronger-than-expected Q3 2025 earnings report, which surpassed both EPS and revenue consensus estimates. However, in January 2026, despite reporting preliminary Q4 2025 revenue that exceeded expectations and providing 2026 guidance that aligned with consensus, the stock saw a slight decline and continued to drift lower. This indicated that positive operational performance might have already been priced in, or the forward-looking statements did not provide enough upside surprise to maintain the earlier momentum.
2. Balanced Analyst Sentiment and Price Target Adjustments. While a significant number of analysts maintain a generally positive "Outperform" or "Buy" rating for INSP, with average price targets suggesting substantial upside, there has also been a period of analyst adjustments. Some analysts lowered their price targets during this period, even while keeping positive ratings. This mix of optimistic long-term outlooks tempered by recent cautious adjustments in price targets likely contributed to the stock consolidating rather than making a definitive upward or downward move.
Show more
Stock Movement Drivers
Fundamental Drivers
The 1.9% change in INSP stock from 10/31/2025 to 2/2/2026 was primarily driven by a 20.8% change in the company's P/E Multiple.| (LTM values as of) | 10312025 | 2022026 | Change |
|---|---|---|---|
| Stock Price ($) | 72.08 | 73.45 | 1.9% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 861 | 883 | 2.5% |
| Net Income Margin (%) | 6.2% | 5.0% | -18.1% |
| P/E Multiple | 40.0 | 48.4 | 20.8% |
| Shares Outstanding (Mil) | 30 | 29 | 0.6% |
| Cumulative Contribution | 1.9% |
Market Drivers
10/31/2025 to 2/2/2026| Return | Correlation | |
|---|---|---|
| INSP | 1.9% | |
| Market (SPY) | 2.0% | 17.2% |
| Sector (XLV) | 7.9% | 19.6% |
Fundamental Drivers
The -41.0% change in INSP stock from 7/31/2025 to 2/2/2026 was primarily driven by a -36.2% change in the company's Net Income Margin (%).| (LTM values as of) | 7312025 | 2022026 | Change |
|---|---|---|---|
| Stock Price ($) | 124.54 | 73.45 | -41.0% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 840 | 883 | 5.1% |
| Net Income Margin (%) | 7.9% | 5.0% | -36.2% |
| P/E Multiple | 55.6 | 48.4 | -13.1% |
| Shares Outstanding (Mil) | 30 | 29 | 1.3% |
| Cumulative Contribution | -41.0% |
Market Drivers
7/31/2025 to 2/2/2026| Return | Correlation | |
|---|---|---|
| INSP | -41.0% | |
| Market (SPY) | 10.3% | 19.2% |
| Sector (XLV) | 19.9% | 26.4% |
Fundamental Drivers
The -62.0% change in INSP stock from 1/31/2025 to 2/2/2026 was primarily driven by a -72.4% change in the company's P/E Multiple.| (LTM values as of) | 1312025 | 2022026 | Change |
|---|---|---|---|
| Stock Price ($) | 193.50 | 73.45 | -62.0% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 756 | 883 | 16.8% |
| Net Income Margin (%) | 4.4% | 5.0% | 15.4% |
| P/E Multiple | 174.9 | 48.4 | -72.4% |
| Shares Outstanding (Mil) | 30 | 29 | 1.9% |
| Cumulative Contribution | -62.0% |
Market Drivers
1/31/2025 to 2/2/2026| Return | Correlation | |
|---|---|---|
| INSP | -62.0% | |
| Market (SPY) | 16.6% | 29.0% |
| Sector (XLV) | 7.4% | 29.7% |
Fundamental Drivers
The -71.0% change in INSP stock from 1/31/2023 to 2/2/2026 was primarily driven by a -88.1% change in the company's P/S Multiple.| (LTM values as of) | 1312023 | 2022026 | Change |
|---|---|---|---|
| Stock Price ($) | 253.06 | 73.45 | -71.0% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 348 | 883 | 153.4% |
| P/S Multiple | 20.5 | 2.4 | -88.1% |
| Shares Outstanding (Mil) | 28 | 29 | -3.8% |
| Cumulative Contribution | -71.0% |
Market Drivers
1/31/2023 to 2/2/2026| Return | Correlation | |
|---|---|---|
| INSP | -71.0% | |
| Market (SPY) | 77.5% | 26.4% |
| Sector (XLV) | 22.2% | 23.7% |
Price Returns Compared
| 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | Total [1] | |
|---|---|---|---|---|---|---|---|
| Returns | |||||||
| INSP Return | 22% | 9% | -19% | -9% | -50% | -18% | -60% |
| Peers Return | 7% | -18% | -29% | 48% | -10% | 5% | -13% |
| S&P 500 Return | 27% | -19% | 24% | 23% | 16% | 1% | 85% |
Monthly Win Rates [3] | |||||||
| INSP Win Rate | 58% | 58% | 50% | 50% | 17% | 0% | |
| Peers Win Rate | 44% | 52% | 48% | 50% | 44% | 38% | |
| S&P 500 Win Rate | 75% | 42% | 67% | 75% | 67% | 50% | |
Max Drawdowns [4] | |||||||
| INSP Max Drawdown | -12% | -36% | -50% | -38% | -61% | -18% | |
| Peers Max Drawdown | -22% | -43% | -48% | -18% | -32% | -2% | |
| S&P 500 Max Drawdown | -1% | -25% | -1% | -2% | -15% | -1% | |
[1] Cumulative total returns since the beginning of 2021
[2] Peers: PEN, GMED, MASI, NVCR, DAVI.
[3] Win Rate = % of calendar months in which monthly returns were positive
[4] Max drawdown represents maximum peak-to-trough decline within a year
[5] 2026 data is for the year up to 2/2/2026 (YTD)
How Low Can It Go
| Event | INSP | S&P 500 |
|---|---|---|
| 2022 Inflation Shock | ||
| % Loss | -61.6% | -25.4% |
| % Gain to Breakeven | 160.3% | 34.1% |
| Time to Breakeven | Not Fully Recovered days | 464 days |
| 2020 Covid Pandemic | ||
| % Loss | -53.7% | -33.9% |
| % Gain to Breakeven | 116.0% | 51.3% |
| Time to Breakeven | 86 days | 148 days |
| 2018 Correction | ||
| % Loss | -35.0% | -19.8% |
| % Gain to Breakeven | 53.7% | 24.7% |
| Time to Breakeven | 63 days | 120 days |
Compare to PEN, GMED, MASI, NVCR, DAVI
In The Past
Inspire Medical Systems's stock fell -61.6% during the 2022 Inflation Shock from a high on 7/14/2023. A -61.6% loss requires a 160.3% gain to breakeven.
Preserve Wealth
Limiting losses and compounding gains is essential to preserving wealth.
Asset Allocation
Actively managed asset allocation strategies protect wealth. Learn more.
About Inspire Medical Systems (INSP)
AI Analysis | Feedback
Here are 1-3 brief analogies for Inspire Medical Systems (INSP):
- Edwards Lifesciences for sleep apnea.
- Like Medtronic, but focused exclusively on implantable devices for sleep apnea.
AI Analysis | Feedback
- Inspire System: An implantable neurostimulation device and associated therapy for the treatment of moderate to severe obstructive sleep apnea.
AI Analysis | Feedback
Inspire Medical Systems (INSP) primarily sells its Inspire therapy device to other companies within the healthcare sector, rather than directly to individuals. Their customers are the healthcare providers and facilities where the Inspire procedure is performed and patients receive care. The company does not typically disclose specific "major customer companies" by name, as their sales are distributed across a broad network of healthcare providers. Publicly traded medical device companies rarely have a single customer or a few customers that account for 10% or more of their revenue unless they are selling components to a finished product manufacturer or have a limited number of large distributors. Inspire's SEC filings do not indicate any single customer accounting for a material portion of their net revenues. However, the categories of companies that serve as their customers include: * **Hospitals:** These are the primary sites where the Inspire device is implanted and patients receive both surgical and follow-up care. * **Ambulatory Surgery Centers (ASCs):** As outpatient facilities increasingly perform complex procedures, Inspire therapy is also offered in these specialized surgical centers. * **Sleep Centers and ENT Clinics:** While not always the direct purchasers of the device itself (hospitals or ASCs usually are), these specialized clinics are crucial partners. They diagnose patients, refer them for Inspire therapy, and manage the pre- and post-operative care, effectively acting as "customer" channels for patient flow and clinical support.AI Analysis | Feedback
null
AI Analysis | Feedback
Timothy P. Herbert, Chairman, President and Chief Executive Officer
Timothy P. Herbert founded Inspire Medical Systems in 2007, a company that was spun out of Medtronic. Prior to founding Inspire, he spent 11 years at Medtronic plc, holding various management positions in product development, clinical research, sales, marketing, and healthcare reimbursement. He holds a B.S. in electrical engineering and an M.B.A.
Rick Buchholz, Chief Financial Officer
Rick Buchholz has served as Chief Financial Officer since May 2014. He will be stepping down from his current position effective December 31, 2025, and will continue in a financial advisory role until late February 2026. Before joining Inspire, Mr. Buchholz served as the Chief Financial Officer, Secretary, and Treasurer at superDimension, Ltd., a medical device manufacturer that was acquired by Covidien plc in 2012. He played a significant role in Inspire's growth, overseeing the increase in revenue from $4 million to over $800 million by 2024, the company's initial public offering, and its achievement of profitability. He holds a B.B.A. and is a Certified Public Accountant (inactive).
Randy Ban, Executive Vice President, Patient Access and Therapy Development
Randy Ban assumed the role of Executive Vice President, Patient Access and Therapy Development in January 2025, having previously served as Chief Commercial Officer from July 2019 to November 2024. He joined Inspire in 2009. His prior experience includes serving as Vice President of Global Marketing, Cardiac Rhythm Management at Boston Scientific. From 1994 to 2008, he held various sales and marketing leadership positions at Guidant Corporation, which was acquired by Boston Scientific in 2006. Mr. Ban began his career at Eli Lilly and Company in 1990 and holds a B.S. in marketing and an M.B.A. He intends to retire on January 30, 2026.
Bryan K. Phillips, Senior Vice President, General Counsel, Chief Compliance Officer, and Corporate Secretary
Bryan K. Phillips joined Inspire in January 2021. Before Inspire, he was Chief Legal Officer of Cerevel Therapeutics Holdings, Inc., a biopharmaceutical company, from December 2019 to January 2021. From 2005 to November 2019, he held various positions at Surmodics, Inc., a medical technology company, including Senior Vice President, Legal and Human Resources, General Counsel, and Secretary. He also served as Patent Counsel at Guidant Corporation's Cardiac Rhythm Management Group from 2001 to 2005. Mr. Phillips holds a B.S. in mechanical engineering and a J.D.
John Rondoni, Chief Product and Innovation Officer
John Rondoni has served as Chief Product and Innovation Officer since May 2025, after being the Chief Technology Officer from May 2022 to May 2025. He possesses over 20 years of experience in the medical devices and digital healthcare solutions markets. Mr. Rondoni joined Inspire in 2008 and has held various product, clinical, and business development roles both in the U.S. and internationally. Prior to joining Inspire, he developed peripheral and central neuromodulation therapies for Medtronic. He is an inventor on over 100 U.S. patents and holds a B.S. and M. Eng. from the Massachusetts Institute of Technology.
AI Analysis | Feedback
The key risks to Inspire Medical Systems (INSP) are primarily associated with challenges in new product introductions, the potential impact of emerging pharmaceutical treatments, and regulatory considerations.
- Challenges and Execution Risks Related to the Inspire V Product Launch: Inspire Medical Systems has experienced significant operational failures and delays with the launch of its Inspire V sleep apnea device. These issues include inadequate training for medical centers, delays in software updates for claims processing, and an existing surplus of older devices, which affected demand for the new product. This led to a substantial reduction in the company's 2025 earnings per share guidance and a significant drop in stock value. Furthermore, these operational setbacks have resulted in proposed class-action lawsuits alleging that the company misled investors about the commercial readiness and demand for Inspire V.
- Competition from GLP-1 Weight Loss Therapies: There is a growing concern that GLP-1 weight loss drugs could potentially affect Inspire's addressable market. As weight loss can sometimes alleviate obstructive sleep apnea, these therapies could reduce the need for Inspire's device in some patients.
- Regulatory Risks Regarding Medical Software Classification: Inspire Medical Systems faces the risk of the FDA changing its current enforcement discretion regarding medical software products. This could potentially lead to the reclassification of applications like SleepSync™ as medical devices, subjecting them to more stringent regulations. Such a reclassification could necessitate complex approval processes, halt marketing efforts, or trigger product recalls, leading to substantial costs and operational disruptions.
AI Analysis | Feedback
The potential market entry of Nyxoah SA's Genio system into the United States. Nyxoah's Genio system is a competing hypoglossal nerve stimulation therapy for obstructive sleep apnea, similar to Inspire's core product. The Genio system has already received regulatory approvals in several international markets (e.g., Europe, Australia) and is actively undergoing clinical trials for FDA approval in the U.S. Should it gain FDA approval and launch, it would introduce direct competition to Inspire Medical Systems in its primary market, potentially impacting market share, pricing power, and differentiation.
AI Analysis | Feedback
The addressable market for Inspire Medical Systems' main product, Inspire therapy for obstructive sleep apnea (OSA), is as follows:
- The estimated market in the U.S. alone is over $10 billion.
- Approximately 23 million adults in the U.S. have moderate to severe OSA.
AI Analysis | Feedback
Inspire Medical Systems (INSP) is anticipated to drive future revenue growth over the next 2-3 years through several key strategies and market dynamics:
- Continued Adoption and Enhanced Performance of the Inspire 5 System: The successful launch and high adoption rate of the Inspire 5 system are expected to be significant growth drivers. This new system offers improved surgical efficiency and enhanced patient outcomes, and its more cost-effective manufacturing contributes to higher gross margins. Physician training for the Inspire 5 system is largely complete, with a high percentage of centers already implementing the new technology.
- Expansion of Provider Network and Capacity: Inspire Medical Systems is focused on increasing the capacity of its provider partners to treat more patients. This includes strategies such as training advanced practice providers and certifying additional surgeons qualified to implant Inspire therapy.
- Increased Direct-to-Consumer (DTC) Marketing Efforts: The company is investing more in direct-to-consumer marketing to drive high-quality patient flow. These efforts aim to raise patient awareness and generate increased demand for Inspire therapy.
- International Market Expansion: Inspire Medical Systems has demonstrated robust international growth, with international revenue surging significantly in recent quarters. Continued expansion into new global markets is expected to contribute to overall revenue growth.
- Favorable Impact of GLP-1 Medications and Reimbursement Changes: The introduction of GLP-1 medications is noted to be increasing interest in sleep health and drawing more patients into clinics. This trend is expected to potentially make a larger pool of higher BMI patients eligible for Inspire therapy after weight loss. Additionally, positive reimbursement changes anticipated to take effect in January 2026 are also expected to enhance access to the therapy.
AI Analysis | Feedback
Share Repurchases
- In August 2025, Inspire Medical Systems authorized a new share repurchase program of up to $200 million, set to expire in August 2027.
- Under this 2025 program, the company completed $50 million in share repurchases during Q3 2025, leaving $150 million available as of September 30, 2025.
- In August 2024, the Board authorized Inspire's first share repurchase program of up to $150 million, which included a $75 million accelerated share repurchase transaction completed in early 2025 and an additional $75 million purchased by March 31, 2025, completing the program.
Share Issuance
- Inspire Medical Systems' shares outstanding slightly decreased by -0.77% over the last year.
- As of September 30, 2025, approximately 29.06 million shares of common stock were outstanding.
- As of September 30, 2025, 1,380,904 shares were available for issuance under the company's equity incentive plan.
Outbound Investments
- In July 2025, Inspire Medical Systems made a Later Stage VC investment in Restera.
- A $4.0 million non-cash impairment of a strategic investment was recorded in Q2 2025.
Capital Expenditures
- Capital expenditures increased from $5 million in 2021 to $39 million in 2024.
- Projected capital expenditures anticipate $28 million for 2025, increasing to $70 million by 2029.
- These expenditures support continuous innovation, product development (including the Inspire V system launch), and expansion of the U.S. sales organization and footprint.
Latest Trefis Analyses
Research & Analysis
Invest in Strategies
Wealth Management
Peer Comparisons
| Peers to compare with: |
Financials
| Median | |
|---|---|
| Name | |
| Mkt Price | 89.70 |
| Mkt Cap | 7.5 |
| Rev LTM | 1,334 |
| Op Inc LTM | 133 |
| FCF LTM | 153 |
| FCF 3Y Avg | 93 |
| CFO LTM | 203 |
| CFO 3Y Avg | 140 |
Growth & Margins
| Median | |
|---|---|
| Name | |
| Rev Chg LTM | 14.6% |
| Rev Chg 3Y Avg | 17.2% |
| Rev Chg Q | 10.5% |
| QoQ Delta Rev Chg LTM | 2.5% |
| Op Mgn LTM | 6.1% |
| Op Mgn 3Y Avg | 8.6% |
| QoQ Delta Op Mgn LTM | 0.5% |
| CFO/Rev LTM | 15.1% |
| CFO/Rev 3Y Avg | 10.1% |
| FCF/Rev LTM | 11.2% |
| FCF/Rev 3Y Avg | 5.9% |
Valuation
| Median | |
|---|---|
| Name | |
| Mkt Cap | 7.5 |
| P/S | 3.4 |
| P/EBIT | 27.8 |
| P/E | 28.5 |
| P/CFO | 16.9 |
| Total Yield | 1.2% |
| Dividend Yield | 0.0% |
| FCF Yield 3Y Avg | 1.1% |
| D/E | 0.0 |
| Net D/E | -0.0 |
Returns
| Median | |
|---|---|
| Name | |
| 1M Rtn | 2.7% |
| 3M Rtn | -0.3% |
| 6M Rtn | 3.7% |
| 12M Rtn | -20.6% |
| 3Y Rtn | -18.3% |
| 1M Excs Rtn | 0.8% |
| 3M Excs Rtn | -1.7% |
| 6M Excs Rtn | -4.2% |
| 12M Excs Rtn | -38.7% |
| 3Y Excs Rtn | -90.4% |
Price Behavior
| Market Price | $73.45 | |
| Market Cap ($ Bil) | 2.2 | |
| First Trading Date | 05/03/2018 | |
| Distance from 52W High | -62.8% | |
| 50 Days | 200 Days | |
| DMA Price | $103.99 | $109.21 |
| DMA Trend | down | up |
| Distance from DMA | -29.4% | -32.7% |
| 3M | 1YR | |
| Volatility | 102.1% | 71.9% |
| Downside Capture | 151.19 | 153.48 |
| Upside Capture | 134.26 | 30.23 |
| Correlation (SPY) | 17.9% | 29.0% |
| 1M | 2M | 3M | 6M | 1Y | 3Y | |
|---|---|---|---|---|---|---|
| Beta | 0.04 | -0.59 | 1.60 | 1.70 | 1.08 | 1.13 |
| Up Beta | 2.55 | -3.60 | 8.04 | 5.52 | 1.30 | 1.37 |
| Down Beta | -2.81 | -2.32 | -2.36 | 0.04 | 0.91 | 0.85 |
| Up Capture | -65% | -172% | 178% | 31% | 26% | 44% |
| Bmk +ve Days | 11 | 22 | 34 | 71 | 142 | 430 |
| Stock +ve Days | 12 | 20 | 30 | 61 | 114 | 364 |
| Down Capture | 413% | 361% | 146% | 198% | 129% | 108% |
| Bmk -ve Days | 9 | 19 | 27 | 54 | 109 | 321 |
| Stock -ve Days | 8 | 21 | 31 | 63 | 134 | 384 |
[1] Upside and downside betas calculated using positive and negative benchmark daily returns respectively
Based On 1-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with INSP | |
|---|---|---|---|---|
| INSP | -61.3% | 71.7% | -1.01 | - |
| Sector ETF (XLV) | 7.1% | 17.2% | 0.24 | 29.6% |
| Equity (SPY) | 16.0% | 19.2% | 0.64 | 28.9% |
| Gold (GLD) | 66.9% | 23.7% | 2.11 | 1.2% |
| Commodities (DBC) | 7.0% | 16.3% | 0.23 | 13.9% |
| Real Estate (VNQ) | 2.9% | 16.5% | -0.00 | 22.6% |
| Bitcoin (BTCUSD) | -19.7% | 39.9% | -0.46 | 10.1% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 5-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with INSP | |
|---|---|---|---|---|
| INSP | -17.8% | 60.5% | -0.07 | - |
| Sector ETF (XLV) | 7.3% | 14.5% | 0.33 | 31.5% |
| Equity (SPY) | 14.1% | 17.1% | 0.66 | 37.4% |
| Gold (GLD) | 19.9% | 16.6% | 0.97 | 5.0% |
| Commodities (DBC) | 11.4% | 18.9% | 0.49 | 8.2% |
| Real Estate (VNQ) | 4.5% | 18.8% | 0.15 | 28.9% |
| Bitcoin (BTCUSD) | 20.9% | 57.6% | 0.56 | 18.8% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 10-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with INSP | |
|---|---|---|---|---|
| INSP | 11.7% | 60.6% | 0.50 | - |
| Sector ETF (XLV) | 10.6% | 16.6% | 0.53 | 39.4% |
| Equity (SPY) | 15.9% | 17.9% | 0.76 | 42.2% |
| Gold (GLD) | 15.0% | 15.3% | 0.81 | 5.3% |
| Commodities (DBC) | 8.3% | 17.6% | 0.39 | 13.4% |
| Real Estate (VNQ) | 5.8% | 20.8% | 0.25 | 33.8% |
| Bitcoin (BTCUSD) | 71.1% | 66.4% | 1.10 | 16.5% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Returns Analyses
Earnings Returns History
Expand for More| Forward Returns | |||
|---|---|---|---|
| Earnings Date | 1D Returns | 5D Returns | 21D Returns |
| 1/12/2026 | -4.6% | ||
| 11/3/2025 | 15.3% | 16.8% | 90.0% |
| 8/4/2025 | -32.4% | -38.7% | -34.1% |
| 5/5/2025 | 2.0% | -1.4% | -13.1% |
| 1/13/2025 | -13.4% | -12.2% | -9.1% |
| 11/4/2024 | 3.3% | 4.8% | 2.2% |
| 7/29/2024 | 6.2% | 19.0% | 50.2% |
| 5/7/2024 | -33.5% | -35.4% | -36.3% |
| ... | |||
| SUMMARY STATS | |||
| # Positive | 15 | 13 | 9 |
| # Negative | 10 | 11 | 15 |
| Median Positive | 6.8% | 5.6% | 23.4% |
| Median Negative | -11.6% | -16.7% | -13.1% |
| Max Positive | 31.8% | 39.1% | 90.0% |
| Max Negative | -33.5% | -38.7% | -36.3% |
SEC Filings
Expand for More| Report Date | Filing Date | Filing |
|---|---|---|
| 09/30/2025 | 11/03/2025 | 10-Q |
| 06/30/2025 | 08/04/2025 | 10-Q |
| 03/31/2025 | 05/05/2025 | 10-Q |
| 12/31/2024 | 02/10/2025 | 10-K |
| 09/30/2024 | 11/04/2024 | 10-Q |
| 06/30/2024 | 08/06/2024 | 10-Q |
| 03/31/2024 | 05/07/2024 | 10-Q |
| 12/31/2023 | 02/09/2024 | 10-K |
| 09/30/2023 | 11/07/2023 | 10-Q |
| 06/30/2023 | 08/01/2023 | 10-Q |
| 03/31/2023 | 05/02/2023 | 10-Q |
| 12/31/2022 | 02/10/2023 | 10-K |
| 09/30/2022 | 11/01/2022 | 10-Q |
| 06/30/2022 | 08/02/2022 | 10-Q |
| 03/31/2022 | 05/03/2022 | 10-Q |
| 12/31/2021 | 02/15/2022 | 10-K |
Insider Activity
Expand for More| # | Owner | Title | Holding | Action | Filing Date | Price | Shares | Transacted Value | Value of Held Shares | Form |
|---|---|---|---|---|---|---|---|---|---|---|
| 1 | McCormick, Shawn | Direct | Sell | 12042025 | 139.00 | 1,200 | 166,800 | 3,453,594 | Form | |
| 2 | McCormick, Shawn | Direct | Sell | 12012025 | 127.48 | 2,000 | 254,960 | 3,320,344 | Form | |
| 3 | Curet, Myriam | Direct | Buy | 11242025 | 163.84 | 4 | 655 | 552,137 | Form | |
| 4 | Curet, Myriam | Direct | Buy | 11242025 | 148.26 | 1 | 148 | 499,791 | Form | |
| 5 | Curet, Myriam | Direct | Sell | 11242025 | 153.22 | 2 | 306 | 516,211 | Form |
External Quote Links
| Y Finance | Barrons |
| TradingView | Morningstar |
| SeekingAlpha | ValueLine |
| Motley Fool | Robinhood |
| CNBC | Etrade |
| MarketWatch | Unusual Whales |
| YCharts | Perplexity Finance |
| FinViz |
Prefer one of these to Trefis? Tell us why.